Page 57 - ECBIP 2021_Program
P. 57

 MODERATED e-POSTER SESSION 04:
Central airways obstruction and foreign body extraction
PP24
Introduction: Zephyr® valves are unidirectional endobronchial valves used in emphysema, the debilitating and fatal form of COPD. They are reserved for patients with FEV1 between 15% and 45% with heterogeneous or homogenous emphysema presenting symptoms despite optimal medical treatment. This procedure is performed in pulmonary endoscopy. The first step consists of a diagnosis using the Chartis® catheter if there is collateral ventilation, which must be nil to have a positive response to treatment. The valves are then placed using a catheter and can be removed or retracted in the bronchoscope. Our center has been practicing this activity since May 2019. The medical device (MD) received FDA approval in 2018 and was recently placed on the PBRL list (March 2020), which changed the purchase costs and revenues for this procedure.
Objective: The aim of this study is to show the impact of the new ZEPHYR valves on the profitability of the activity.
Material and Methods: The patient files that benefited from this treatment between May 2019 and February 2020 were analysed. The costs related to the MDs used were calculated (Chartis catheter, positionning catheter and valves).The income generated by the patients’ stay was evaluated using the DIM (medical information department). An assessment of the profitability of the activity was carried out.
Results: Over the period, 13 patients were clinically selected for the Zephyr procedure. Among them, 9 patients actually received at least one valve following the diagnosis made using the Chartis catheter. The average cost in DM per patient is 5,769 € for an average income of 4,339 €.The overall balance found a deficit of € 18,731 for the 13 patients. The PBDA registration has reduced the cost of purchasing the valve, but in return, the previously offered diagnostic catheter now comes at a cost. By simulating a similar activity, we find a cost in MD of €5,615 per intervention for a stay revenue of €5,769, to which we can add the reimbursement of the valves, i.e. €9,522 of average revenue per patient. This gives a total profit of €50,781.
Discussion: The new management of endobronchial valves would therefore make it possible to completely reverse the overall balance of this activity, which was previously loss-making, and which has become very profitable since March 2020. This study, based on a simulation of the previous activity, requires a prospective analysis of future interventions.
        NEW MANAGEMENT OF UNIDIRECTIONAL ENDOBRONCHIAL VALVES: TOWARDS A PROFITABLE ACTIVITY?
Fichon Thomas, Delphine Nickers, Benedicte Toublanc, Abir Petit
CHU Amiens Picardie, Amiens, France
         ECBIP 2021 57
6th European Congress
for Bronchology and Interventional Pulmonology
OCTOBER ECBIP 15 - 17
ATHENS - GREECE 2021
Book of Abstracts
    

















































































   55   56   57   58   59